Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6

European Journal of Clinical Pharmacology

Volumn 54, Issue 5, 1998, Pages 437-441

  Hadidi, H ^b   Irshaid, Y ^b   Vagbo C B ^a   Brunsvik, A ^a   Cholerton, S ^c   Zahlsen, K ^b   Idle, J R ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Coumarin; Metabolism; Risk evaluation

Indexed keywords

COUMARIN; DRUG METABOLITE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GAS CHROMATOGRAPHY; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROXYLATION; JORDAN; LIVER TOXICITY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYLATION; JORDAN; MALE; MIXED FUNCTION OXYGENASES; PHENYLACETATES; POLYMORPHISM, GENETIC; UMBELLIFERONES; VARIATION (GENETICS);

EID: 0031875570     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050489     Document Type: Article

References (26)

1. Egun D, O'Kennedy R, Mora E, Cox D, Prosser E, Thornes RD (1990) The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 22: 503-529
2. Rastogi SC, Johansen JD, Menne T (1996) Natural ingredients based cosmetics. Content of selected fragrance scnsitizers. Contact Dermatitis 34: 423-426
3. Hoult JR, Paya M (1996) Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol 27: 713-722
4. Mortmer PS (1997) Therapy approaches for lymphedema. Angiography 48: 87-91
5. Nolte H, Pederson L, Mouridsen HT (1987) Combined treatment of advanced malignant melanoma with coumarin and cimetidine. Anticancer Res 7: 449-450
6. Yagoda A, Petrylak D, Thomson S (1993) Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20: 303-321
7. Cohen AJ (1979) Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. Food Chem Toxicol 17: 277-289
8. Kaighen M, Williams RT (1961) The metabolism of (3 14C) coumarin. J Med Chem 3: 25-43
9. Shilling WH, Crampton RF, Longland RC (1969) Metabolism of coumarin in man. Nature 221: 664-665
10. Cholerton S, Idle ME, Vas A, Gonzalez FJ, Idle JR (1992) Comparison of a novel thin-layer chromatographic-fluorescence detection method with spectrofluorometric method for determination of 7-hydroxycoumarin in human urine. J Chromatogr B Biomed Sci Appl 575: 325-330
11. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O (1992) Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2: 227-233
12. Iscan M, Rostami H, Iscan M, Guray T, Pelkonen O, Rautio A (1994) Interindividuul variability of eoumarin 7-hydroxylation in a Turkish population. Eur J Clin Pharmacol 47: 315-318
13. Endell W, Seidel G (1978) Coumarin toxicity in different strains of mice. Agents Actions 8: 299-302
14. Fentem JH, Fry JR (1992) Metabolism of eoumarin by rat, gerhil, and human liver microsomes. Xenobiotica 22: 357-367
15. Fentem JH, Fry JR (1993) Species differences in the metabolism and hepatoloxicily of eoumarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 104: 1-8
16. Fentem JH, Fry JR, Whiting DA (1991) O-Hydroxyphenylacetaldehyde: a major novel metabolite of eoumarin formed by rat, gerbil and human liver microsomes. Biochem Biophys Res Commun 179: 197-203
17. 14C)coumarin in the rat and marmoset (Callithrix jacchus). Toxicol Lett 45: 299-306
18. 14C)coumarin to polar and covalently bound products by hepatic microsomes from the rat. Syrian hamster, gerbil and human. Food Chem Toxicol 30: 105-115
19. Lush IE, Andrews KM (1978) Genetic variation between mice in their metabolism of eoumarin and its derivatives. Genet Res 31: 177-186
20. Miles JS, Mclaren AW, Forrester LM, Glancy MJ, Lang MA, Wolf CR (1990) Identification of the human liver cytochrome P450 responsible for eoumarin 7-hydroxylase activity. Biochem J 267: 365-371
21. Yamano S, Tatsuno J, Gonzalez FJ (1990) The CYP2A3 gene product catalyses eoumarin 7-hydroxylation in human liver microsomes. Biochemistry 29: 1322-1329
22. Fernandez-Salguero P, Hoffmun SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J-D, Evans W, Idle JR, Gonzalez FJ (1995) A genetic polymorphism in eoumarin 7-hydroxylation: sequence of the human CYP2 A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57: 651-660
23. Hadidi H, Zahlsen K, Idle JR, Cholerton S (1997) A single amino acid substitution (Leu160His) in cvtochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of eoumarin. Food Chem Toxicol 35: 903-907
24. Shimada T, Yamazaki H, Guengerich FP (1996) Ethnic-related dillerenees in eoumarin 7-hydroxylation activities catalyzed by cytochrome P450-2A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotiea 26: 395-403
25. Mahgouh A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet ii: 5S4-5S6
26. Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, Nagashima K, Funae Y, Green C, Kinoshita M, Kamalaki T (1998) A new deleted allele in the human cytochrome P450-2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to eoumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 8: 239-249